Early Real-World Results: A Major Step Toward Liver Cancer Detection

We’re excited to share promising early results from our collaboration with Zymo Research Corp., marking a key milestone in our journey to develop a highly accurate, affordable blood test for liver cancer detection.

In this initial evaluation, Zymo sequenced a small set of 12 biobank blood samples, consisting of both early-stage liver cancer and non-cancer liver disease cases. These samples were then analyzed using OmicXHealth’s proprietary AI/ML methylation models.

The outcome was encouraging:

• Two of our models correctly identified 10 out of 12 cases.

  
  

• A third model identified 11 out of 12, demonstrating strong potential for consistent, real-world performance.

  
  

These results confirm that our approach isn’t limited to controlled, public datasets — it works on actual clinical samples.

With these findings, we’ve now locked in the lab process (“wet lab”) and calibrated our software models to the assay developed through this collaboration. This alignment between wet lab methods and computational analysis ensures repeatable and scalable results as we move forward.

Our next batch of clinical samples will follow the same validated protocol and settings. If we observe similar levels of accuracy, we’ll be ready to advance toward CLIA Laboratory Developed Test (LDT) validation — the regulated pathway that allows U.S. laboratories to commercially offer clinically reliable tests without requiring the longer FDA approval process.

Early detection of liver cancer remains one of the biggest challenges in oncology. By combining epigenetic biomarkers and AI-driven pattern recognition, we’re building a test designed to detect cancer at its earliest and most treatable stages.

While these are still early results, they represent an important proof point: our models can generalize to real-world clinical data and deliver meaningful insights that could one day save lives.

We’re deeply grateful to our partners at Zymo Research Corp. for their collaboration and scientific rigor throughout this process. Together, we’re moving closer to making accessible, accurate early cancer detection a reality.

Stay tuned for updates as we scale our next round of testing and progress toward clinical validation.

Onward.